Fresenius SE & Co. KGaA is a German health care company based in Bad Homburg, Germany. The Fresenius Group provides products and services for dialysis, hospitals as well as inpatient and outpatient medical care. In addition, the company focuses on hospital management as well as on engineering and services for medical centers and other health care facilities. The company is a component of the Euro Stoxx 50 stock market index.
|Kommanditgesellschaft auf Aktien with Societas Europaea as partner with unlimited liability|
|Stephan Sturm (CEO and chairman of the management board), Gerd Krick (Chairman of the supervisory board)|
|Products||Kidney dialysis, infusion pumps, drugs, hospitals, medical care|
|Revenue||€29.083 billion (2016)|
|€4.327 billion (2016)|
|€1.593 billion (2016)|
|Total assets||€46.447 billion (end 2016)|
|Total equity||€20.420 billion (end 2016)|
Number of employees
The Fresenius Group is made up of four divisions:
- Fresenius Medical Care (a publicly traded company of which Fresenius owns 30.8%): focuses on patients with chronic kidney failure
- Fresenius Helios is Germany’s largest hospital operator
- Fresenius Kabi is a supplier of essential drugs, clinical nutrition products, medical devices
- Fresenius Vamed plans, develops and manages healthcare facilities.
Another arm of Fresenius Kabi is Fresenius Kabi Oncology Plc. It produces generics of intravenous oncology products such as Paclitaxel, Irinotecan, Oxaliplatin, Gemcitabine, Cytarabine, Carboplatin, Topotecan, Docetaxel and Epirubicin.
Fresenius owns the Helios Kliniken, which has more than 110 hospitals and more than 30,000 beds, treating over 4 million patients annually. The hospital operator is the biggest provider of inpatient and outpatient care in Germany.
In 2016 Fresenius bought the largest Spanish hospital group, the Grupo Hospitalario Quirónsalud for 5.76 Billion euros and merged it into the Helios Group, establishing the biggest hospital group of Europe.
The North American branch of Fresenius Medical Care is headquartered in Waltham, Massachusetts.
The company was founded by Eduard Fresenius (1874–1946) in 1912.
In 1946, Fresenius left the company to Else Kröner, his foster-daughter and protege, who was still in pharmacy school at the time. Else Kröner rescued the company from significant debts by laying off the majority of staff and restructuring the business. By Kröner's death in 1988, the company was an international leader. Kröner's will endowed the Else Kröner-Fresenius-Foundation, which funds medical research.
In September 2006, Helios Kliniken GmbH obtained antitrust approval from the German antitrust authorities for the acquisition of a majority stake of Humaine Kliniken.
HUMAINE operates six acute and post acute care hospitals in the fields of neurology, oncology and traumatology On July 16, 2007, the company completed its conversion from an Aktiengesellschaft (AG - German public limited company) to a Societas Europaea, the European Union-wide equivalent. The company changed its legal status once again on January 28, 2011, becoming a Kommanditgesellschaft auf Aktien (KGaA - German partnership limited by shares) with a Societas Europaea as a partner with unlimited liability (SE & Co. KGaA).
In August 2008 Fresenius Kabi acquired Dabur Pharma Ltd by acquiring 73.3% of the share capital. In September, Fresenius Kabi, a business segment of Fresenius SE, has completed the acquisition of APP Pharmaceuticals, Inc.
In October 2011, the company has agreed to acquire 51 percent of the share capital in Katholisches Klinikum Duisburg hospital. In the same month Helios Kliniken GmbH, a subsidiary of Fresenius, acquired 94.7% of the share capital in Damp Group.
In November 2014, the company announced that its Russian partners – Sistema JSFC and Zenitco Finance Management LLC – had agreed to terminate their joint venture agreement that had been established in April 2014. The termination was prompted by changing political and regulatory circumstances in the region, according to a statement from Fresenius.
In January 2016, Fresenius Kabi announced that it would acquire Becton, Dickinson and Company's prescription drug business. In February, Fresenius Helios acquired the municipal hospital in Velbert located in the German state of North Rhine-Westphalia. In December, Fresenius Helios, received anti trust approval to acquire, IDC Salud Holding S.L.U. (Quirónsalud), Spain’s largest private hospital operator for €5.76 billion, with the transaction expected to close in January 2017.
- Fresenius SE & Co. KGaA
- Fresenius Medical Care
- NxStage Medical, Inc.
- Fresenius Helios
- Helios Kliniken GmbH
- Humaine Kliniken
- IDC Salud Holding S.L.U. (Quirónsalud)
- Damp Group
- Helios Kliniken GmbH
- Fresenius Kabi AG
- Labesfal SA
- Fresenius Kabi Oncology Plc
- Dabur Pharma Ltd
- APP Pharmaceuticals, Inc
- Fenwal Holdings, Inc.
- Fresenius Vamed
- Fresenius Medical Care
In 2012 a paper was published raising concerns regarding the use of hydroxyethyl starch in sepsis. Fresenius Kabi, who makes the product, has warned legal action against the author, Anders Perner, as they disagree with the results. The academic community has raised concerns regarding this sort of behavior by a corporation.
In 2015, the British branch of the Fresenius Kabi Group pleaded guilty to breaches of United Kingdom's Medicines Act 1968 and was fined £500,000 with costs by the Sheffield Crown Court for supplying faulty insulin syringes containing no insulin for manufacturers Calea UK to a local hospital, leading to the death of patient Neil Judge from diabetic ketoacidosis in 2010.
- "Annual Report 2016" (PDF). Fresenius. Retrieved 27 October 2017.
- Frankfurt Stock Exchange Archived November 19, 2015, at the Wayback Machine
- "Group Overview - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- unknown, unknown (22 December 2016). "Spanische Kartellbhoerde gibt gruenes Licht - Fresenius uebernimmt-klinikbetreiber Quironsalud". Handelsblatt Gmbh. Retrieved 26 April 2017.
- "Fresenius". Fresenius. Retrieved 2016-02-07.
- "Fresenius Kabi closed acquisition of I.V. drug company Labesfal - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "Fresenius Kabi continues growth strategy and acquires I.V. drug company - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "HELIOS obtains antitrust approval to acquire HUMAINE Kliniken - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- Fresenius SE (2007-07-16). "Fresenius completes conversion into a European Company (SE)". Retrieved 2007-08-12.
- "Fresenius successfully completes share conversion and change of legal form - First trading day of Fresenius SE & Co. KGaA shares January 31, 2011". Fresenius. 28 January 2011. Retrieved 24 February 2011.
- "Fresenius closes APP acquisition - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "HELIOS acquires majority of maximum care hospital in Duisburg, North-Rhine Westphalia - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "HELIOS continues expansion in German hospital market, acquires Damp Group - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "History - Fresenius".
- Jonathan Gould; Ludwig Burger (13 September 2013). "Rhoen-Klinikum to sell hospitals to Fresenius in $4 billion deal". Reuters.
- "Fresenius says Fresenius Kabi and Russian partners terminate JV" (Press release). Reuters. 6 November 2014.
- "Fresenius Kabi acquires Ready-to-Administer Drugs and U.S. Pharmaceutical Plant from Becton Dickinson - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "Fresenius Helios acquires hospital in North Rhine-Westphalia with more than 500 beds - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "Fresenius Helios acquires largest private Spanish hospital group Quirónsalud - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- "Fresenius Helios receives antitrust approval to acquire Quirónsalud - Fresenius SE & Co. KGaA". Retrieved 15 May 2017.
- Burger, Ludwig. "Fresenius Medical banks on home dialysis with $2 billion NxStage acquisition". reuters.com. Retrieved 23 September 2017.
- "Fresenius Medical Care to Acquire NxStage Medical, Inc. to Strengthen Its Vertically Integrated Dialysis Business (NASDAQ:NXTM)". ir.nxstage.com. Retrieved 23 September 2017.
- Perner, A; Haase, N; Guttormsen, AB; Tenhunen, J; Klemenzson, G; Åneman, A; Madsen, KR; Møller, MH; Elkjær, JM; Poulsen, LM; Bendtsen, A; Winding, R; Steensen, M; Berezowicz, P; Søe-Jensen, P; Bestle, M; Strand, K; Wiis, J; White, JO; Thornberg, KJ; Quist, L; Nielsen, J; Andersen, LH; Holst, LB; Thormar, K; Kjældgaard, AL; Fabritius, ML; Mondrup, F; Pott, FC; Møller, TP; Winkel, P; Wetterslev, J; 6S Trial Group; Scandinavian Critical Care Trials Group (Jul 12, 2012). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–34. doi:10.1056/NEJMoa1204242. PMID 22738085.
- Wojcik, Jeppe (July 24, 2012). "Pharma giant threatens Danish scientist". ScienceNordic. Retrieved 13 August 2012.
- "Insulin-free syringe firms fined over diabetic death". BBC News. 9 July 2015.
- Ford, Steve (9 July 2015). "Firms fined for supplying hospital with faulty syringes". Nursing Times.